Literature DB >> 10757470

Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1.

L E Cutting1, C W Koth, C P Burnette, M T Abrams, W E Kaufmann, M B Denckla.   

Abstract

Using quantitative magnetic resonance imaging morphometry, we report that the whole brain volumes of patients with neurofibromatosis-1 are significantly larger than normal, confirm the prevalence of macrocephaly as about 50%, and report that macrocephaly in patients with neurofibromatosis-1 does not appear to be related to the familial or sporadic origin of the neurofibromatosis-1 or to the presence or absence of T2-weighted hyperintensities. No strong relationship emerged between the extent of neurofibromatosis-1-associated impairment of cognitive functions and degree of macrocephaly; however, the macrocephalic neurofibromatosis-1 group did have a significant verbal impairment relative to the nonmacrocephalic neurofibromatosis-1 group in vocabulary (P < .009).

Entities:  

Mesh:

Year:  2000        PMID: 10757470     DOI: 10.1177/088307380001500303

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  13 in total

1.  Unidentified bright objects in neurofibromatosis type 1.

Authors:  Anita Choudhary; Suvasini Sharma; Naveen Sankhyan; Sheffali Gulati; Atin Kumar
Journal:  Indian J Pediatr       Date:  2010-03       Impact factor: 1.967

Review 2.  Neural phenotypes of common and rare genetic variants.

Authors:  Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson
Journal:  Biol Psychol       Date:  2008-02-23       Impact factor: 3.251

3.  Corpus callosum morphology and microstructure assessed using structural MR imaging and diffusion tensor imaging: initial findings in adults with neurofibromatosis type 1.

Authors:  E L Wignall; P D Griffiths; N G Papadakis; I D Wilkinson; L I Wallis; O Bandmann; P E E Cowell; N Hoggard
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

4.  Brain imaging findings and social/emotional problems in Israeli children with neurofibromatosis type 1.

Authors:  Rony Cohen; Tamar Steinberg; Liora Kornreich; Sharon Aharoni; Ayelet Halevy; Avinoam Shuper
Journal:  Eur J Pediatr       Date:  2014-07-16       Impact factor: 3.183

Review 5.  Neurocognitive dysfunction in children with neurofibromatosis type 1.

Authors:  Tena L Rosser; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

6.  Brain and behaviour phenotyping of a mouse model of neurofibromatosis type-1: an MRI/DTI study on social cognition.

Authors:  L I Petrella; Y Cai; J V Sereno; S I Gonçalves; A J Silva; M Castelo-Branco
Journal:  Genes Brain Behav       Date:  2016-07-05       Impact factor: 3.449

Review 7.  Diagnosis and management of neurofibromatosis type 1.

Authors:  B R Korf
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 6.030

8.  Developmental malformation of the corpus callosum: a review of typical callosal development and examples of developmental disorders with callosal involvement.

Authors:  Lynn K Paul
Journal:  J Neurodev Disord       Date:  2010-09-23       Impact factor: 4.025

Review 9.  Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder?

Authors:  Juliana Magdalon; Sandra M Sánchez-Sánchez; Karina Griesi-Oliveira; Andréa L Sertié
Journal:  Int J Mol Sci       Date:  2017-03-18       Impact factor: 5.923

10.  Characterizing the microstructural basis of "unidentified bright objects" in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis.

Authors:  Thibo Billiet; Burkhard Mädler; Felice D'Arco; Ronald Peeters; Sabine Deprez; Ellen Plasschaert; Alexander Leemans; Hui Zhang; Bea Van den Bergh; Mathieu Vandenbulcke; Eric Legius; Stefan Sunaert; Louise Emsell
Journal:  Neuroimage Clin       Date:  2014-04-13       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.